Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07090785 | A Study of LY4088044 in Healthy Participants | PHASE1 | RECRUITING | 104 | — | — | Jul 24, 2025 | Jul 1, 2027 | Jun 3, 2026 | 6 | United States, New Zealand +1 |
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4088044 (Part A) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4088044 administered intravenously (IV) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Administered IV |
| LY4088044 (Part B) | EXPERIMENTAL | SAD of LY4088044 administered subcutaneously (SC) |
| Placebo (Part B) | PLACEBO_COMPARATOR | Administered SC |
| LY4088044 (Part C) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4088044 administered IV |
| Placebo (Part C) | PLACEBO_COMPARATOR | Administered IV |
| Name | Type | Description |
|---|---|---|
| LY4088044 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring * Have a body mass index (BMI) within the range 18.5 to 30 kilogram per square meter (kg/m²) Exclusion Criteria: * A...